Medicare paid too much for newly available generic drugs

Medicare and its beneficiaries wasted $111 million on generic drugs, according to a report by the Office of the Inspector General. The OIG investigation found that payment amounts were much higher than market prices for an extended period for newly available generic drugs under review. Generic versions of certain drugs were administered or dispensed to beneficiaries, but Medicare was still paying brand-level prices. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.